Hangzhou-based clinical research organization Tigermed has announced impressive interim results for 2026, reflecting strong growth driven by strategic acquisitions, expanded global operations, and a broad pipeline of drug and medical device projects.
- Signed strategic deals with Hisun, Insilico, 3SBio, and a European pharma giant
- Acquired Teddy Laboratory and Shanghai Bioquick to broaden R&D and lab testing
- Expanded global workforce to nearly 12,000 across 43 countries
What happened
Tigermed announced its unaudited interim results for the first half of 2026, highlighting significant growth in revenues and operational scale. The company signed multiple strategic cooperation agreements with leading pharmaceutical and AI-focused companies, enhancing its capabilities in clinical trials, AI-powered research, and early-stage drug development. Additionally, Tigermed completed acquisitions of Teddy Laboratory and Shanghai Bioquick to integrate preclinical R&D and lab services within its clinical supply chain.
Why it matters
Tigermed continues to solidify its position as the leading clinical research organization in China and one of the top 10 globally. Its broad service portfolio now spans early drug discovery, clinical trials, regulatory affairs, pharmacovigilance, and manufacturing services. The acquisitions and strategic partnerships enable Tigermed to offer fully integrated R&D solutions, supporting pharmaceutical clients throughout the drug development lifecycle.
The company’s global expansion into markets including the U.S., Australia, Europe, and Asia-Pacific reflects growing international demand for outsourced clinical and laboratory services. The surge in clinical project counts, new customers, and geographic diversification contributes to Tigermed’s competitive edge and revenue growth, positioning it strongly amid rapid industry transformation driven by innovation and globalization.
What to watch next
Market watchers will monitor Tigermed’s ability to sustain its growth momentum throughout 2026 amid competitive pressures and evolving regulatory environments worldwide. Particular attention will focus on the integration progress of recent acquisitions and expansion of its CDMO manufacturing capacity in the U.S., which could enhance service offerings and margins.